Retinalize, LLC is pleased to announce that it has signed contracts with several large multi-physician Ophthalmology groups in Florida to begin using the Retinalytics SVM analysis technology to assist physicians in the diagnosis of macular degeneration. Retinalize, LLC is a 50%/50% joint venture between Health Discovery Corporation (OTCBB: HDVY), a molecular diagnostics leader in the use of patent protected advanced mathematical techniques for personalized medicine, and Doctors Optimal Formula LLC, a physician exclusive anti-aging, health and wellness company. Age-related Macular Degeneration (AMD) is the leading cause of blindness in US adults 55 years and older and is a progressive eye disease affecting more than 15 million Americans, with over 200,000 new cases diagnosed each year. These new ophthalmology physician contracts are in addition to the recently signed exclusive agreement with the 5500 member National EYEPA Coalition which is exclusive to optometrists. “It’s incredibly exciting to see the positive responses we have seen since recently launching the Retinalytics SVM analysis technology,” states Howard Loff, M.D., CEO of Retinalyze, LLC. “In addition to having signed up the National EYEPA Coalition, we have now been fortunate to also sign up some of the largest Ophthalmology practices in Florida. We expect this trend to continue throughout the United States as well as internationally. As a result of the positive feedback that we are receiving from both optometrists and ophthalmologists alike, we hope Retinalytics SVM analysis technology will become the new standard of care in assisting doctors in their examination of ophthalmic diseases.” Stephen D. Barnhill, M.D., Chairman and CEO of Health Discovery Corporation, added, “We are extremely pleased to see the rapid growth in the number of both optometrists and ophthalmologists signing up to use the Retinalytics SVM analysis technology for macular degeneration. I expect as the additional modules for diabetic retinopathy, hypertensive retinopathy and glaucoma are released, the revenue generated by our current and future optometry and ophthalmology customers will be significantly increased.”
Eye Doctors and patients interested in learning more about the NATIONAL EYEPA COALITION, please visit www.nationaleyepa.com.About Doctors Optimal Formula LLC Having been founded by medical doctors, Doctors Optimal Formula prides itself on providing the best, scientifically formulated nutritional supplements and anti-aging skin care available today! Focusing on maintaining and improving the health and well-being of our customers, Doctors Optimal Formula has become vertically integrated to encompass all aspects of healthcare, such as Vision Care Plans, Prescription Pharmacy Plans and a physician provider network of over 10,000 physicians. For more information, visit www.DoctorsOptimalFormula.com. About Health Discovery Corporation Health Discovery Corporation is a molecular diagnostics company that uses advanced mathematical techniques to analyze large amounts of data to uncover patterns that might otherwise be undetectable. It operates primarily in the emerging field of personalized medicine where such tools are critical to scientific discovery. Its primary business consists of licensing its intellectual property and developing its own product line of biomarker-based diagnostic tests that include human genes and genetic variations, as well as gene, protein, and metabolic expression differences and image analysis in digital pathology and radiology. For more information, see www.healthdiscoverycorp.com. Forward-Looking Statements This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, the accuracy of which is necessarily subject to risks and uncertainties, including, without limitation, statements regarding future performance, opportunities and investments, and anticipated results in general. From time to time the Company may make other forward-looking statements in relation to other matters, including without limitation, commercialization plans and strategic partnerships. Actual results may differ materially due to a variety of factors, including, among other things, the acceptance of our approach to applying mathematics, computer science and physics into the disciplines of biology, organic chemistry and medicine and our products and technologies associated with those approaches, the ability to develop and commercialize new drugs, therapies or other products based on our approaches, and other factors set forth from time to time in the Company’s Securities and Exchange Commission filings.
All forward-looking statements and cautionary statements included in this document are made as of the date hereof based on information available to the Company as of the date hereof, and the Company assumes no obligation to update any forward-looking statement or cautionary statement.